NRx Pharmaceuticals (NASDAQ:NRXP) Receives “Buy” Rating from HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $40.00 price target on the stock. Several other equities research analysts also recently commented on NRXP. Zacks Research raised NRx Pharmaceuticals to a “hold” rating in […]

Leave a Reply

Your email address will not be published.

Previous post TD Cowen Begins Coverage on Semtech (NASDAQ:SMTC)
Next post Needham & Company LLC Reaffirms Buy Rating for Roku (NASDAQ:ROKU)